Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.
Gene Expression Profiling
Macrophages
Myeloid-Derived Suppressor Cells
Neuroblastoma
Tumor Microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
21
06
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
High-risk neuroblastoma is a pediatric cancer with still a dismal prognosis, despite multimodal and intensive therapies. Tumor microenvironment represents a key component of the tumor ecosystem the complexity of which has to be accurately understood to define selective targeting opportunities, including immune-based therapies. We combined various approaches including single-cell transcriptomics to dissect the tumor microenvironment of both a transgenic mouse neuroblastoma model and a cohort of 10 biopsies from neuroblastoma patients, either at diagnosis or at relapse. Features of related cells were validated by multicolor flow cytometry and functional assays. We show that the immune microenvironment of MYCN-driven mouse neuroblastoma is characterized by a low content of T cells, several phenotypes of macrophages and a population of cells expressing signatures of myeloid-derived suppressor cells (MDSCs) that are molecularly distinct from the various macrophage subsets. We document two cancer-associated fibroblasts (CAFs) subsets, one of which corresponding to CAF-S1, known to have immunosuppressive functions. Our data unravel a complex content in myeloid cells in patient tumors and further document a striking correspondence of the microenvironment populations between both mouse and human tumors. We show that mouse intratumor T cells exhibit increased expression of inhibitory receptors at the protein level. Consistently, T cells from patients are characterized by features of exhaustion, expressing inhibitory receptors and showing low expression of effector cytokines. We further functionally demonstrate that MDSCs isolated from mouse neuroblastoma have immunosuppressive properties, impairing the proliferation of T lymphocytes. Our study demonstrates that neuroblastoma tumors have an immunocompromised microenvironment characterized by dysfunctional T cells and accumulation of immunosuppressive cells. Our work provides a new and precious data resource to better understand the neuroblastoma ecosystem and suggest novel therapeutic strategies, targeting both tumor cells and components of the microenvironment.
Sections du résumé
BACKGROUND
High-risk neuroblastoma is a pediatric cancer with still a dismal prognosis, despite multimodal and intensive therapies. Tumor microenvironment represents a key component of the tumor ecosystem the complexity of which has to be accurately understood to define selective targeting opportunities, including immune-based therapies.
METHODS
We combined various approaches including single-cell transcriptomics to dissect the tumor microenvironment of both a transgenic mouse neuroblastoma model and a cohort of 10 biopsies from neuroblastoma patients, either at diagnosis or at relapse. Features of related cells were validated by multicolor flow cytometry and functional assays.
RESULTS
We show that the immune microenvironment of MYCN-driven mouse neuroblastoma is characterized by a low content of T cells, several phenotypes of macrophages and a population of cells expressing signatures of myeloid-derived suppressor cells (MDSCs) that are molecularly distinct from the various macrophage subsets. We document two cancer-associated fibroblasts (CAFs) subsets, one of which corresponding to CAF-S1, known to have immunosuppressive functions. Our data unravel a complex content in myeloid cells in patient tumors and further document a striking correspondence of the microenvironment populations between both mouse and human tumors. We show that mouse intratumor T cells exhibit increased expression of inhibitory receptors at the protein level. Consistently, T cells from patients are characterized by features of exhaustion, expressing inhibitory receptors and showing low expression of effector cytokines. We further functionally demonstrate that MDSCs isolated from mouse neuroblastoma have immunosuppressive properties, impairing the proliferation of T lymphocytes.
CONCLUSIONS
Our study demonstrates that neuroblastoma tumors have an immunocompromised microenvironment characterized by dysfunctional T cells and accumulation of immunosuppressive cells. Our work provides a new and precious data resource to better understand the neuroblastoma ecosystem and suggest novel therapeutic strategies, targeting both tumor cells and components of the microenvironment.
Identifiants
pubmed: 36054452
pii: jitc-2022-004807
doi: 10.1136/jitc-2022-004807
pmc: PMC9362821
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33566112
Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Br J Cancer. 2021 May;124(11):1754-1756
pubmed: 33758330
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Cancer Res. 2022 Jan 15;82(2):187-194
pubmed: 34764204
Cancer Discov. 2021 Nov;11(11):2693-2706
pubmed: 34635571
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2049-54
pubmed: 16609014
Sci Immunol. 2020 Feb 21;5(44):
pubmed: 32086381
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Immunother Cancer. 2019 Aug 28;7(1):230
pubmed: 31462270
Nat Rev Cancer. 2020 Sep;20(9):485-503
pubmed: 32694624
J Immunol. 2014 Aug 15;193(4):1690-700
pubmed: 25009204
Cancer Res. 2011 Apr 1;71(7):2664-74
pubmed: 21324923
Semin Immunol. 2020 Apr;48:101417
pubmed: 33077325
J Clin Oncol. 1996 Feb;14(2):405-14
pubmed: 8636750
Clin Cancer Res. 2020 Mar 15;26(6):1420-1431
pubmed: 31848188
Nat Rev Immunol. 2014 Jun;14(6):392-404
pubmed: 24854589
Cell. 2021 Apr 15;184(8):2033-2052.e21
pubmed: 33765443
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
J Pathol. 2016 Oct;240(2):211-23
pubmed: 27425378
J Clin Oncol. 2009 Mar 1;27(7):1007-13
pubmed: 19171716
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
J Clin Oncol. 2012 Oct 1;30(28):3525-32
pubmed: 22927533
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Cancers (Basel). 2017 Jun 18;9(6):
pubmed: 28629162
EMBO J. 1997 Jun 2;16(11):2985-95
pubmed: 9214616
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Cancer Immunol Res. 2018 Nov;6(11):1388-1400
pubmed: 30266715
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
N Engl J Med. 2010 Sep 30;363(14):1324-34
pubmed: 20879881
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894
EMBO J. 2020 Oct 1;39(19):e104063
pubmed: 32790115
Cell Immunol. 2017 Dec;322:1-14
pubmed: 29079339
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Sci Transl Med. 2020 Nov 25;12(571):
pubmed: 33239386
Cancer Immunol Immunother. 2005 Apr;54(4):400-6
pubmed: 15449039
Cancers (Basel). 2020 Jul 25;12(8):
pubmed: 32722460
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169
pubmed: 30897608
Nat Commun. 2020 Jan 21;11(1):404
pubmed: 31964880
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Nature. 2021 Nov;599(7885):477-484
pubmed: 34732890
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Semin Cancer Biol. 2011 Oct;21(4):245-55
pubmed: 21958944